1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018
2. Protein kinase B: emerging mechanisms of isoform-specific regulation of cellular signaling in cancer;Wadhwa;Anticancer Drugs,2017
3. W.G. Wierda, J.C. Byrd, J.S. Abramson, S.F. Bilgrami, G. Bociek, D. Brander, J. Brown, A.A. Chanan-Khan, J.C. Chavez, S.E. Coutre, R.S. Davis, C.D. Fletcher, B. Hill, B.S. Kahl, M. Kamdar, L.D. Kaplan, N. Khan, T.J. Kipps, S. Ma, S. Malek, A. Mato, C. Mosse, V.T. Neppalli, M. Shadman, T. Siddiqi, D. Stephens, N. Wagner, M. Dwyer, H. Sundar, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) - Head and Neck Cancers - Version 2.2018. , 2018 (accessed January 21.2019).
4. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: a subanalysis of Asian patients versus the global population in checkmate 141;Kiyota;Oral Oncol.,2017
5. FDA approval summary: pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy;Larkins;Oncologist,2017